98%
921
2 minutes
20
Objectives: Prostatitis caused by antibiotic-resistant Escherichia coli poses a significant treatment challenge, and phage therapy is emerging as a promising antibacterial strategy. Here we report the case of a patient with prostatitis caused by an extended spectrum β-lactamase-producing E. coli successfully treated with oral doxycycline and two phage cocktails. The use of doxycycline was supported by the detection of Mycoplasma spp. in the patient's urine. We also tested the same phage-antibiotic combination against a panel of different E. coli strains in vitro.
Methods: A patient received oral SES and PYO phage cocktails alongside oral doxycycline for 30 days. The MIC values of doxycycline and phages alone and in combination were evaluated by checkboard assay versus five E. coli isolates, including the patient's strain. Synergy was assessed using a modified fractional inhibitory concentration index. Data were analysed by synogram and an interaction plot based on the percentage reduction of the absorbance values (OD) between untreated control and treated samples. Growth curves were performed over 24 h to monitor bacterial replication in the presence/absence of phage and/or antibiotic.
Results: After treatment microbiological cultures were negative and symptoms remitted. A synergistic/additive effect between doxycycline and the phages was observed in vitro in three out of five E. coli isolates. Synogram analysis showed a synergistic effect versus one strain, while an additive effect was observed for the other four isolates. Growth curve analysis demonstrated enhanced bacterial growth inhibition for up to 12 h with the combined treatment compared with either therapy alone.
Conclusions: Although the E. coli strain was resistant to doxycycline, the antibiotic was administered specifically to target the Mycoplasma infection. Interestingly, the enhanced in vitro activity observed when the antibiotic was combined with phages versus E. coli suggests that this combination may be effective at eradicating chronic prostatitis caused by extended spectrum β-lactamase-producing E. coli.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijantimicag.2025.107571 | DOI Listing |
World J Urol
September 2025
Department of Pharmacology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil.
Purpose: To evaluate the impact of MRP inhibition by MK571 on prostate hypercontractility in diet-induced obesity, based on the hypothesis that this intervention enhances intracellular cAMP and cGMP signaling.
Methods: Adult C57BL/6 mice were divided into three groups: (i) lean, (ii) obese, and (iii) obese + MK571 (5 mg/kg/day, 14 days). The prostate was isolated for immunohistochemistry, biochemistry and functional assays.
Clin Pharmacol Drug Dev
September 2025
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan, China.
Tamsulosin is a highly selective α1A adrenergic receptor antagonist that can relax smooth muscles in the urethra, bladder neck, and prostate and improve urinary disorders. It is therefore widely used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. The aim of this study is to evaluate the pharmacokinetic (PK) characteristics and bioequivalence of 2 different formulations (tamsulosin sustained-release tablets and tamsulosin sustained-release capsules) in healthy Chinese subjects.
View Article and Find Full Text PDFAnn Afr Med
September 2025
Department of Pathology, Dr. Lal Path Labs, New Delhi, India.
Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks.
View Article and Find Full Text PDFCancer Med
September 2025
The Key Laboratory of Tumor Stem Cell Research of Liaoning Province, Dalian Medical University, Dalian, China.
Background: Prostate cancer is one of the principal malignancies threatening human health, and the development of castration resistance often constitutes a major cause of treatment failure in its management.
Methods: To elucidate the potential association between programmed death-ligand 1 (PD-L1) and castration resistance in prostate cancer, we analyzed the expression levels of PD-L1 in both primary prostate cancer tissues and castration-resistant prostate cancer (CRPC) specimens as well as in corresponding cell lines by using western blots and immunohistochemistry. Then, we explored the specific mechanisms through transcriptomic sequencing technology.
Pain Manag
September 2025
Serviço de Reabilitação de Adultos 3, Centro de Medicina de Reabilitação de Alcoitão, Alcabideche, Portugal.
Pudendal neuropathy is a cause of pelvic pain, specifically pudendal neuralgia. The pudendal nerve is related to sensory, motor, and autonomic functions. We present the case of a 41-year-old man who suffered from chronic pelvic pain.
View Article and Find Full Text PDF